MedPath

Prospective multicenter Study to evaluate the Effect of tight and systematic monitoring by Ultrasound on Therapy and Outcome in Patients with early rheumatoid Arthritis

Conditions
rheumatoid arthritis
M05
Seropositive rheumatoid arthritis
Registration Number
DRKS00010485
Lead Sponsor
Charité Universitätsmedizin Berlin -Med. Klinik mit SP Rheumatologie und Klin. Immunologie
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
453
Inclusion Criteria

•Patients, at least 18 years of age, with currently active RA with or without re-ceiving DMARDs. Active disease is defined as DAS 28 > 3.2 and at least swollen joint count (SJC) = 3 and tender joint count (TJC) = 3 included in the 28 joint count.
•Early RA (= 2 years from time of onset of arthritic symptoms)

Exclusion Criteria

•Patients receiving biologics
•Patients with other chronic inflammatory articular disease or systemic autoimmune disease
•Patients with erosions in conventional radiography taken less than 3 months before start of study
•Patients participating in other studies
•Any active infection, a history of recurrent clinically significant infection, a history of recurrent bacterial infections with encapsulated organisms (known Hepatitis B, C and HIV)
•Primary or secondary immunodeficiency
•History of cancer with curative treatment not longer than 5 years ago except basal-cell carcinoma of the skin that had been excised
•Evidence of significant uncontrolled concomitant diseases or serious and / or uncontrolled diseases that are likely to interfere with the evaluation of the patient's safety and of the study outcome
•Women lactating, pregnant, nursing or of childbearing potential with a positive pregnancy test or planned pregnancy.
•Women of childbearing potential without adequate contraception (medically acceptable methods are contraceptive implant, contraceptive injection, intrauterine device (IUD), or oral contraceptives taken for at least 3 months, which the patient agrees to continue using during the study, or a double-barrier method which must consist of a combination of any of the following: diaphragma, cervical cap, comdom, or spermicide)
•History of alcohol, drug or chemical abuse (defined as impaired / questionable reliability) as well as neurotic personality.
•Neuropathy that can interfere with filling out the patient's questionnaires
•History of a severe psychological illness or condition
•Severe heart failure (New York Heart Association Class III and IV) or severe, uncontrolled cardiac disease
•Women lactating, pregnant, nursing or child bearing potential with a positive pregnancy test or planned pregnancy.
•Women of childbearing potential without adequate contraception (medically acceptable methods are contraceptive implant, contraceptive injection
•no written consent

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath